{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mental+Retardation%2C+X-Linked&page=3",
    "query": {
      "condition": "Mental Retardation, X-Linked",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 246,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mental+Retardation%2C+X-Linked&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mental+Retardation%2C+X-Linked&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T10:54:37.458Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01586455",
      "title": "Human Placental-Derived Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Mucopolysaccharidosis VI",
        "Adrenoleukodystrophy",
        "Niemann-Pick Disease",
        "Metachromatic Leukodystrophy",
        "Wolman Disease",
        "Krabbe's Disease",
        "Gaucher's Disease",
        "Fucosidosis",
        "Batten Disease",
        "Severe Aplastic Anemia",
        "Diamond-Blackfan Anemia",
        "Amegakaryocytic Thrombocytopenia",
        "Myelodysplastic Syndrome",
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Human Placental Derived Stem Cell",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "0 Years to 55 Years"
      },
      "enrollment_count": 43,
      "start_date": "2013-04",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Valhalla, New York • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01586455"
    },
    {
      "nct_id": "NCT07480564",
      "title": "Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "TSHA-102",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Taysha Gene Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "3 Years",
        "sex": "FEMALE",
        "summary": "2 Years to 3 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2026-05-08",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07480564"
    },
    {
      "nct_id": "NCT05003648",
      "title": "Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Adrenoleukodystrophy",
        "Restless Legs Syndrome"
      ],
      "interventions": [
        {
          "name": "Pramipexole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2023-04-01",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003648"
    },
    {
      "nct_id": "NCT02705677",
      "title": "Biobanking of Rett Syndrome and Related Disorders",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rett Syndrome",
        "MECP2 Duplication",
        "CDKL5",
        "FOXG1 Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 752,
      "start_date": "2017-09-01",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Oakland, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02705677"
    },
    {
      "nct_id": "NCT04279314",
      "title": "Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "Trofinetide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "FEMALE",
        "summary": "5 Years to 21 Years · Female only"
      },
      "enrollment_count": 154,
      "start_date": "2020-01-29",
      "completion_date": "2022-08-19",
      "has_results": true,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04279314"
    },
    {
      "nct_id": "NCT01449240",
      "title": "Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hunter Syndrome"
      ],
      "interventions": [
        {
          "name": "No treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "Up to 70 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2012-11-12",
      "completion_date": "2013-12-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 5,
      "location_summary": "Decatur, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01449240"
    },
    {
      "nct_id": "NCT06430385",
      "title": "ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome"
      ],
      "interventions": [
        {
          "name": "ION440",
          "type": "DRUG"
        },
        {
          "name": "Sham procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "2 Years to 65 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2024-10-21",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Aurora, Colorado • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06430385"
    },
    {
      "nct_id": "NCT04571970",
      "title": "RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis Type II (MPS II)"
      ],
      "interventions": [
        {
          "name": "RGX-121",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "5 Years to 17 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2021-03-11",
      "completion_date": "2024-05-23",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04571970"
    },
    {
      "nct_id": "NCT00920647",
      "title": "A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hunter Syndrome"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "OTHER"
        },
        {
          "name": "Idursulfase IT (1 mg)",
          "type": "DRUG"
        },
        {
          "name": "Idursulfase IT (10 mg)",
          "type": "DRUG"
        },
        {
          "name": "Idursulfase IT (30 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "3 Years to 18 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2009-11-18",
      "completion_date": "2012-10-29",
      "has_results": true,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920647"
    },
    {
      "nct_id": "NCT03802799",
      "title": "Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "ZYN002 - Cannabidiol Transdermal Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zynerba Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "3 Years to 29 Years"
      },
      "enrollment_count": 476,
      "start_date": "2018-11-09",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-04T10:54:37.458Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Culver City, California • Irvine, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03802799"
    }
  ]
}